Diffuse Liver Metastases with Minimal Hepatic Dysfunction
Related Experiment Video
Updated: Nov 5, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Rony Moon1, Elaine J Chiao2, Zoee U D'Costa2
1University of California, Los Angeles.
Abstract:
A 47-year-old woman with stage IV breast cancer and liver metastases presented with abdominal pain. Contrast-enhanced computed tomography (CT) of the abdomen and pelvis demonstrated marked hepatomegaly with metastatic lesions replacing most of the hepatic parenchyma. Laboratory evaluations demonstrated only modest elevation of her liver function tests with mildly elevated alkaline phosphatase. She also had preserved hepatic synthetic function. We suggest this was due to several factors. The liver's substantial functional reserve and regenerative capacity even with up to 80% parenchymal replacement. Tumor metastases forming expansive nodules that displace rather than eradicate hepatocytes. Compensatory hypertrophy of non-malignant hepatic parenchyma with increased metabolic activity, and active hepatic compensation for space-occupying disease known as the "hepatostat" effect. These mechanisms combined to maintain liver function even in an advanced metastatic state. We further suggest that her Alkaline phosphatase elevation was multifactorial due to bone metastases, systemic inflammation and prolonged immobility. Additionally, her younger age, lack of alcohol use, stable nutritional status and other comorbidity also protected her from more severe liver dysfunction.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

